Prelude Therapeutics Incorporated · NASDAQ:PRLD

Prelude Therapeutics — Technical Presentation (June 2023)

15 slides from Prelude Therapeutics's technical presentation, June 2023

  1. Slide 1: Phase 1 Study of PRMT5 Inhibitor PRT811 in Glioma or Uveal Melanoma

    A Phase 1 Study of the Protein Arginine Methyltransferase 5 (PRMT5) Brain-Penetrant Inhibitor PRT811 in Patients with Recurrent High-Grade Glioma or Uveal Melanoma Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  2. Slide 2: Background

    Background Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  3. Slide 3: Study Design NCT04089449

    Study Design<br />NCT04089449 Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  4. Slide 4: Patient Disposition

    Patient Disposition Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  5. Slide 5: Patient Baseline Characteristics

    Patient Baseline Characteristics Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  6. Slide 6: Patient Disease Characteristics

    Patient Disease Characteristics Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  7. Slide 7: Safety Summary

    Safety Summary Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  8. Slide 8: Treatment-Emergent AEs ≥15%

    Treatment-Emergent AEs ≥15% Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  9. Slide 9: Best Overall Response

    Best Overall Response Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  10. Slide 10: Confirmed CR in a Patient With Glioma

    Confirmed CR in a <br />Patient With Glioma Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  11. Slide 11: Clinical Benefit Rate

    Clinical Benefit Rate Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  12. Slide 12: Treatment Duration and PFS in Patients With Glioma (n=38)

    Treatment Duration and PFS in Patients With Glioma (n=38) Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  13. Slide 13: Treatment Duration and PFS in Patients With Uveal Melanoma (n=23)

    Treatment Duration and PFS in Patients With Uveal Melanoma (n=23) Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  14. Slide 14: Summary

    Summary Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

  15. Slide 15: Acknowledgments

    Acknowledgments Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

Prelude Therapeutics — Technical Presentation (June 2023) on 6ix